Ascelia Pharma
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a Total Nominal Amount of SEK 7.5 Million
Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) issued on 13 September 2024, convertibles to Fenja Capital II A/S (“Fenja Capital”) with an aggregate nominal amount of SEK 7.5 million. Fenja Capital has now requested conversion of all outstanding convertibles whereby a total of 2,218,933 new ordinary shares are issued to Fenja Capital at a conversion price of SEK 3.38 per share.
As a result of the conversion of convertibles, the number of ordinary shares in Ascelia Pharma will increase by 2,218,933, which results in that the total number of outstanding shares in the Company increases from 117,112,647 shares to 119,331,580 shares, whereof 118,244,459 are ordinary shares and 1,087,121 are series C shares. The share capital increases with SEK 2,218,933 from SEK 117,112,647 to SEK 119,331,580. This corresponds to a dilution effect of approximately 1.88 percent of the total number of ordinary shares in the company after the conversion.
The cash runway of Ascelia Pharma is now into the second quarter 2026.
| Datum | 2025-09-02, kl 16:10 |
| Källa | MFN |